Podcast: When lung cancer research gets personal
Lauren Averett Byers, M.D.
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
About Dr. Byers
Dr. Lauren Byers is a Professor and Thoracic Section Chief in the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. Dr. Byers completed her B.A. degree in Molecular Biology at Princeton University in 1998, her M.D.... degree at Baylor College of Medicine in 2003, and M.S. degree in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences in 2009. Following her Clinical Residency in Internal Medicine at Johns Hopkins Hospital, Dr. Byers joined MD Anderson Cancer Center in 2006 as a Clinical Fellow in Medical Oncology and later as an Advanced Scholar Fellow.
As a physician-scientist, Dr. Byers’ research focuses on high-throughput molecular profiling to identify new therapeutic targets, predictive biomarkers, and mechanisms of resistance, especially in the area of Small Cell Lung Cancer (SCLC). H er research led to the first comprehensive framework for classifying SCLC into distinct molecular subtypes. She has rapidly translated these findings into clinical trials and leads a multi-disciplinary translational research team that leverages tumors and liquid biopsies from patients with lung cancer to accelerate the development of personalized treatments and biomarkers.
Dr. Byers serves as PI on multiple awards including NCI R01, U01 and U24 awards focused on lung cancer. She is co-PI for the NCI’s Small Cell Lung Cancer Consortium, Chair of the MD Anderson Cancer Center Multidisciplinary Research Program, co-leader of the MD Anderson Cancer Center Lung CCSG Program, and a project leader in the MD Anderson/UT Southwestern Lung SPORE. As a clinical investigator, Dr. Byers has led a number of clinical trials investigating new therapeutic targets and biomarkers, including the first CAR T-cell for SCLC patients.
Her contributions in SCLC (one of the most recalcitrant cancers) have been recognized in the NCI’s report to the US Congress as among the most impactful advances in the past decade. She has an impressive list of awards, including election to the American Society for Clinical Investigation and the MD Anderson President’s Recognition for Faculty Excellence. She has mentored numerous early career trainees, serves as faculty at the Graduate School of Biomedical Sciences, and serves on several grant review panels, including past Chair of the ASCO Conquer Cancer Grant Selection Committee, and is a standing member on several grant review panels including the NIH Mechanisms of Cancer Therapeutics-2 (MCT2) Study Section.
In the News
Two MD Anderson researchers elected AAAS Fellows
MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell...
Study defines small-cell lung cancer subtypes and distinct...
5 small cell lung cancer questions, answered
2019 Andrew Sabin Family Fellows share passion for Making Cancer...
Intratumoral heterogeneity may be responsible for chemotherapy...
Present Title & Affiliation
Primary Appointment
Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Byers’ research goal is to identify changes in cancer cells at the molecular level that contribute to their growth and drug resistance and apply this knowledge to develop more effective, personalized therapy for patients. Her laboratory - together with the Thoracic Bioinformatics Team, which she co-leads - studies gene and protein profiles obtained from lung cancer cell lines, mouse models, and patient tumors. Dr. Byers’ laboratory research led to the discovery of several novel drug targets for lung cancer and important ways in which cancer cells can become resistant to existing therapies, including immunotherapy. The results generated by her team have led directly to clinical trials with new combinations of drugs that will impact patient care. More recently, Dr. Byers’ group identified transcriptional subtypes tumor of SCLC with unique therapeutic vulnerabilities that be identified using both transcriptional and cfDNA methylation profiling data. Currently, Dr. Byers is examining approaches to personalize treatment for SCLC patients, and to develop novel treatment modalities in the relapsed setting.
Clinical Interests
Dr. Byers is a medical oncologist dedicated to bringing the most promising findings from her research to the bedside. She has translated key findings from her work into clinical trials and new biomarkers that have the potential to improve personalized cancer care for people with lung cancer.
Education & Training
Degree-Granting Education
| 2009 | University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA, MS, Cancer Biology (Specialization in Patient-Based Research) |
| 2003 | Baylor College of Medicine, Houston, TX, USA, MD, Medicine |
| 1998 | Princeton University, Princeton, NJ, USA, BA, Molecular Biology |
Postgraduate Training
| 2009-2010 | Advanced Scholars Program, Medical Oncology Research, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2006-2009 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2003-2006 | Clinical Residency, Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD |
Board Certifications
| 2010 | Medical Oncology, American Board of Internal Medicine |
| 2006 | Internal Medicine, American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2017
Selected Publications
Peer-Reviewed Articles
- Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42(2):225-237.e5, 2024. e-Pub 2024. PMID: 38278149.
- Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities. Cancer Cell 39(3):346-360.e7, 2021. e-Pub 2021. PMID: 33482121.
- Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell Analyses Reveal Increased Intratumoral Heterogeneity after the Onset of Therapy Resistance in Small-cell Lung Cancer. Nat Cancer 1:423-436, 2020. e-Pub 2020. PMID: 33521652.
- Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Anti-tumor Immunity through STING-mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov 9(5):646-661, 2019. e-Pub 2019. PMID: 30777870.
- Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination with Either Veliparib or Placebo in Patients with Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36(23):JCO2018777672, 2018. e-Pub 2018. PMID: 29906251.
- Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA. CHK1 Inhibition in Small Cell Lung Cancer Produces Single-agent Activity in Biomarker-defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res 77(14):3870-3884, 2017. e-Pub 2017. PMID: 28490518.
- de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, 2-Part Trial of Poly (ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov 7(6):620-629, 2017. e-Pub 2017. PMID: 28242752.
- Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan YH, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring Genomic Alterations Define Major Subsets of KRAS - Mutant Lung Adenocarcinoma with Distinct biology, Immune Profiles and Therapeutic Vulnerabilities. Cancer Discov 5(8):860-877, 2015. e-Pub 2015. PMID: 26069186.
- Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM. Multi-platform Analysis of 12 cancer Types Reveals Molecular Classification within and Across Tissues-of-origin. Cell 158(4):929-44, 2014. e-Pub 2014. PMID: 25109877.
- Cancer Genome Atlas Research Network. Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature 511(7511):543-50, 2014. e-Pub 2014. PMID: 25079552.
- Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An Epithelial-mesenchymal Transition (EMT) Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clin Cancer Res Comment in Clinical Cancer Research, 2013 19(1):279-290, 2013. e-Pub 2012. PMID: 23091115.
- Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets including PARP1. Cancer Discov (In the Spotlight, Cancer Discovery, 2012 2(9):798-811, 2012. e-Pub 2012. PMID: 22961666.
- Cancer Genome Atlas Research Network. Comprehensive Genomic Characterization of Squamous Cell Lung Cancers. Nature 489(7417):519-25, 2012. e-Pub 2012. PMID: 22960745.
- Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-cell Lymphoma. N Engl J Med 346(25):1937-47, 2002. PMID: 12075054.
Invited Articles
- Sen T, Gay CM, Byers LA. Targeting DNA Damage Repair in Small Cell Lung Cancer and the Biomarker Landscape. Transl Lung Cancer Res 7(1):50-68, 2018.
Editorials
- Gay CM, Parseghian CM, Byers LA. This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell 37(1):5-7, 2020. PMID: 31951562.
- Stewart CA, Byers LA. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition. Cancer Cell 28(1):4-6, 2015. PMID: 26175409.
Books (edited and written)
- Glisson BS, Byers LA. Pathobiology and Staging of Small Cell Carcinoma of the Lung. Ed(s) Lilenbaum RC, Nicholson A, Jett JR. UpToDate, 2014.
Grant & Contract Support
| Date: | 2021 - 2026 |
| Title: | CPRIT Early Clinical Investigator Award-Carl Gay - Molecular Subtypes as Predictors for Precision Small Cell Lung Cancer Therapeutic Response |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Mentor |
| ID: | RP210159 |
| Date: | 2021 - 2026 |
| Title: | Molecular and Immunological Heterogeneity of Small Cell Lung Cancer (SCLC) and its Impact on Relapse and Therapeutic Response |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator/Project Director |
| ID: | 1U01CA256780-01 |
| Date: | 2021 - 2023 |
| Title: | Generation of Humanisable CTC-DX Models from Anti-PDL1 Progressing SCLC Patients to Evaluate Post-CASPIAN Candidate Combinations |
| Funding Source: | AstraZeneca |
| Role: | Principal Investigator |
| ID: | RCTS #2021-00059068 |
| Date: | 2020 - 2023 |
| Title: | SCLC Molecular Subtypes to Predict Targeted and Immune Therapy Response |
| Funding Source: | Lungevity Foundation |
| Role: | Co-Investigator |
| ID: | Proposal Central ID#716803 |
| Date: | 2020 - 2025 |
| Title: | UT SPORE: Developing New Rationale, personalized Medicine for Lung cancer. Therapeutic Targeting of Replication Stress for Tumor Cell Killing and Anti-tumor Immunity in Small Cell Lung Cancer (SCLC) |
| Funding Source: | NIH/NCI SPORE |
| Role: | Applied/Basic/Clinical Co-Leader |
| ID: | 5P50CA70907-21 |
| Date: | 2020 - 2022 |
| Title: | Evaluation of Pre- and post-treatment Biopsy Tissue from SCLC Patients Treated with the Aurora Kinase B Inhibitor AZD2811-NP on Study NCT02579226 for Biomarker Expression |
| Funding Source: | AstraZeneca |
| Role: | Principal Investigator |
| ID: | RCTS LS 2020-00057699 |
| Date: | 2019 - 2025 |
| Title: | Center for Clinical and Translational Sciences (CCTS) |
| Funding Source: | NIH-NCATS |
| Role: | Co-Investigator and Co-Core Lead - TL1 Program |
| ID: | UL1TR003167 |
| Date: | 2017 - 2022 |
| Title: | Novel Therapeutic Approaches for Enhancing Anti-tumor Immunity in SCLC |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| ID: | U01CA213273-01A1 |
| Date: | 2017 - 2022 |
| Title: | Evaluation of Aurora Kinase B Inhibition in Preclinical Models of SCLC |
| Funding Source: | AstraZeneca |
| Role: | Principal Investigator |
| ID: | LS2018-54380-AM3 |
Patient Reviews
5/5
Listened Carefully to You
5/5
Explanations Easy to Understand
4.9/5
Knew Your Medical History
5/5
Gave Easy to Understand Instructions
4.9/5
Spent Enough Time With You
5/5
Showed Respect for You
5/5
Would Recommend Provider’s Office
4.9/5
Provider Rating 0 - 10
Comments (27)
Yesterday, when we met with Dr. Byers and her team, she allowed the team to come in and talk to us first individually. And then she came in and listened to all of our questions and our concerns and talked to us about a plan that she wanted to give our father to help with...
Hi, Lauren Breyers is always so kind and so aware of what's going on with me. She's given me the best clinical trial in the world and gotten me enrolled in it. I'm so grateful. I've had some missteps with other issues, but they've taken care of that. My clinical advisors...
the only concern we had was with the appointment time, which we noted with doctor since we come from out of town. The appointment time was 1:30P.M. We got there a little early. Was told she was running behind a couple of hours, if we wanted to go eat or something. So we...
I am very grateful to Dr. Byers and her team for all the help they have given me. I am doing so much better than I expected.
She was very thorough in telling me everything about my exams that went on and for future exams. And it really meant a lot to me. Answered every question that I had and health concerns. Thank you.
I haven't actually seen Dr. Byers in a couple of visits, but know she is reviewing my scans and that her NP is fully qualified to manage communications and answer questions.
My provider is Lauren Byers and she is unbelievably helpful. She's very respectful of my issues and she listens carefully and she answers everything I ask and she has a clinical person there with her named Christopher and he's wonderful also. So they have given me a second...
Dr. Byers is very personal and approachable, caring and compassionate
Dr. Byers has one of the most compassionate mannerisms that I've ever seen in a doctor. We just love her. Thank you.
Dr. Byers is excellent. She's very knowledgeable. She's very caring, very helpful. I will say from an overall thing, yesterday the timing was off everywhere in the hospital. So we were there several hours waiting for appointments. But other than that, the doctor and her...
Dr Byers was attentative and interested. Explained all areas of concern to me. And advised me on what further tests etc. I should be looking at
My experiences with Dr. Lauren Byers and her staff have been all very positive.
I am glad that I chose MD Anderson
Dr Byers is so competent and compassionate. I could not ask for a better doctor.
Yes, I had a very good experience with Dr. Byers and her staff. Everyone made me feel comfortable. I was able to ask questions, get answers, and I am looking forward to my treatment plan.
She listened to me. She did not rush
Dr Byers listened and understood that I had already completed cancer treatment it didn't work. Dr Byers was very encouraging about a new clinical trial
She is wonderfully kind and very an excellent practitioner. She Is a pleasure to work with.
Dr. Lauren Byers had really spoken with the clinical team about my lung cancer and its specific mutation and I appreciate her knowing everything. I had sent the records earlier and she had to quickly go through them because they had misplaced them, but anyway, they were...
Yes, we love Dr. Byers. We love everything about her, except she's...we usually have to wait a very long time between when the physician assistant comes in and then when she comes in. That would be my only complaint. Thank you.
I thought she was very attentive and really listened.
Dr. Byers and Catherine both did a great job talking with me about the test I was doing and issues I'm facing.
Excellent beyond measure
Everything was excellent. Very satisfied.
I am blessed to have Dr. Byers as my primary pulmonary oncologist at MD Anderson.
She did an excellent work and I appreciate all the concerns that she has about my personal illness.
Very compassionate. Very knowledgeable. I didn't feel like she hurried through my appointment at all. Answered all my questions. I was extremely pleased. Very glad I decided to come to MDA.
CV information above last modified August 20, 2024
Request an Appointment
Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
Related Links
Clinical Trials
Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.